Ask AI
ProCE Banner Activity

CE / CME

Oral Therapy Adherence: PARP Inhibitors, TKIs, and PIK3/AKT/mTOR Inhibitors

Video

In a recent live symposium, experts discussed indications for and challenges associated with approved PARP inhibitors, HER2-targeted tyrosine kinase inhibitors, and PIK3/AKI/mTOR inhibitors in the management of breast cancer based on findings from key clinical trials. Watch and enhance your knowledge of these oral oncolytics as the faculty summarize the evidence and review patient cases.

Nurse Practitioners/Nurses: 0.50 Nursing contact hours, includes 0.50 hour of pharmacotherapy credit

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: June 16, 2025

Expiration: December 15, 2025

Continue Activity

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Practicing Clinicians Exchange, LLC. and Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca and Merck Sharp & Dohme LLC.

AstraZeneca

Merck Sharp & Dohme, LLC

Partners

Clinical Care Options, LLC

ProCE Banner

Practicing Clinicians Exchange, LLC

ProCE Banner

Target Audience

This activity is intended for nurse practitioners, physician associates, clinical nurse specialists, advanced degree nurses who manage patients, and pharmacists who are part of the care team for patients with breast cancer. 

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners in identifying and addressing factors that affect adherence and persistence to oral therapies for breast cancer. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Assess fundamental issues that affect adherence and persistence to oral anticancer therapy for patients with breast cancer, including patient-, provider- and treatment-related factors and socioeconomic considerations and healthcare disparities

  • Use communication strategies, tools, and resources to assess and address adherence challenges in patients on oral anticancer therapies for breast cancer

  • Apply evidence-based recommendations to effectively mitigate and manage AEs associated with oral anticancer therapies in breast cancer

  • Initiate discussions with patients with breast cancer and their caregivers to assess for and reinforce education on treatment-related AEs and maintain adherence and persistence to prescribed oral anticancer therapy

Disclosure

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Kristi K. Orbaugh, MSN, NP, AOCNP: speaker: AstraZeneca, Bristol Myers Squibb, DSI, Exelixis, Lilly, Pfizer, Sobi, Stemline.

Kimberly Podsada, MSN, NP-C, CNS: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo, Novartis, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 16, 2025, through December 15, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (Partners) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 contact hours, including 0.5 hours of pharmacotherapy credit.

Continuing Pharmacy Education

Partners designates this continuing education activity for 0.5 contact hours (0.05 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008073-0000-25-189-H01-P

Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until December 15, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 0.5 Interprofessional Continuing Education (IPCE) credits for learning and change.